rivoglitazone HCl

DRUG3 trials

Sponsors

Daiichi Sankyo, Daiichi Sankyo Co., Ltd.

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes

CompletedNCT00575874

Daiichi Sankyo Co., Ltd.Type 2 Diabetes

Start: 2007-08-31End: 2009-01-31Target: 150Updated: 2009-02-09

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes

CompletedNCT00575874

Daiichi Sankyo Co., Ltd.Type 2 Diabetes

Start: 2007-08-31End: 2009-01-31Target: 150Updated: 2009-02-09

Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes

CompletedNCT00575471

Daiichi Sankyo Co., Ltd.Type 2 Diabetes

Start: 2007-07-31End: 2008-03-31Updated: 2009-03-02

Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes

CompletedNCT00575471

Daiichi Sankyo Co., Ltd.Type 2 Diabetes

Start: 2007-07-31End: 2008-03-31Updated: 2009-03-02

Phase 3

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

TerminatedNCT00571519

Daiichi SankyoType 2 Diabetes Mellitus

Start: 2007-11-14End: 2008-05-23Updated: 2021-05-26

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

TerminatedNCT00571519

Daiichi SankyoType 2 Diabetes Mellitus

Start: 2007-11-14End: 2008-05-23Updated: 2021-05-26